229 related articles for article (PubMed ID: 21198946)
1. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.
Barker J; Horn EJ; Lebwohl M; Warren RB; Nast A; Rosenberg W; Smith C;
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):758-64. PubMed ID: 21198946
[TBL] [Abstract][Full Text] [Related]
2. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.
Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S
Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
Montaudié H; Sbidian E; Paul C; Maza A; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP
J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():12-8. PubMed ID: 21388454
[TBL] [Abstract][Full Text] [Related]
4. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
Lynch M; Higgins E; McCormick PA; Kirby B; Nolan N; Rogers S; Lally A; Vellinga A; Omar H; Collins P
JAMA Dermatol; 2014 Aug; 150(8):856-62. PubMed ID: 24964792
[TBL] [Abstract][Full Text] [Related]
5. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
[TBL] [Abstract][Full Text] [Related]
6. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
[TBL] [Abstract][Full Text] [Related]
8. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.
Zachariae H; Heickendorff L; Søgaard H
Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate: improving safety profile.
Grills C; Burge S
Australas J Dermatol; 2006 Aug; 47(3):178-81. PubMed ID: 16866998
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.
Kalb RE; Strober B; Weinstein G; Lebwohl M
J Am Acad Dermatol; 2009 May; 60(5):824-37. PubMed ID: 19389524
[TBL] [Abstract][Full Text] [Related]
11. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
Chládek J; Simková M; Vanecková J; Hroch M; Vávrová J; Hůlek P
J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1007-14. PubMed ID: 22882190
[TBL] [Abstract][Full Text] [Related]
12. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
13. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients.
Boffa MJ; Smith A; Chalmers RJ; Mitchell DM; Rowan B; Warnes TW; Shomaf M; Haboubi NY
Br J Dermatol; 1996 Oct; 135(4):538-44. PubMed ID: 8915142
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate for psoriasis: current European practice. A postal survey.
Boffa MJ
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):196-202. PubMed ID: 15752290
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis.
Weinstein GD; Cox JW; Suringa DW; Millard MM; Kalser M; Frost P
Arch Dermatol; 1970 Dec; 102(6):613-8. PubMed ID: 5501902
[No Abstract] [Full Text] [Related]
16. A review of methotrexate-associated hepatotoxicity.
Bath RK; Brar NK; Forouhar FA; Wu GY
J Dig Dis; 2014 Oct; 15(10):517-24. PubMed ID: 25139707
[TBL] [Abstract][Full Text] [Related]
17. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?
Thomas JA; Aithal GP
Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024
[TBL] [Abstract][Full Text] [Related]
18. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?
Kaffenberger BH; Kaffenberger JA; Wong H; Jarjour W; Levin D; Bechtel MA
Int J Dermatol; 2015 Jul; 54(7):752-6. PubMed ID: 26108262
[TBL] [Abstract][Full Text] [Related]
20. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.
Rademaker M; Gupta M; Andrews M; Armour K; Baker C; Foley P; Gebauer K; George J; Rubel D; Sullivan J
Australas J Dermatol; 2017 Aug; 58(3):166-170. PubMed ID: 27402434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
